In his presentation at Ending Age-Related Diseases 2020, LEAF board member Javier Noris discussed the Longevity Impact Fund, the reasons why biotechnology funding has been lacking, the “valley of death” that must be crossed in order to fully fund early-stage research through the clinical trial process, and new ways in which venture capital can fund high-risk biotechnology ventures.
| HELP SPREAD THE WORD |
| Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension: |
|
|
| Thank You! |
Write a comment: